COMPASS Pathways(US:CMPS) 智通财经网·2025-06-24 00:50Core Viewpoint - Compass Pathways' disappointing Phase III trial results for psilocybin treatment of treatment-resistant depression (TRD) led to a significant decline in stock prices across the psychedelic drug sector, with Compass's stock dropping by 49% [1][2]. Group 1: Trial Results and Market Reaction - The Phase III trial (COMP005) for COMP360 showed a MADRS score improvement of only 3.6 points compared to placebo, which, while statistically significant, fell short of analysts' expectations of at least 5 points and was lower than the company's previous Phase II data of 6.6 points [2][3]. - The underwhelming results raised concerns about the efficacy, sustainability, and commercial potential of psilocybin, leading to a broader sell-off in the psychedelic drug sector [2][3]. - Other companies in the psychedelic space, such as atai Life Sciences, MindMed, Cybin, and GH Research, experienced stock declines ranging from 5% to over 15% following the news [2][3]. Group 2: Impact on Other Companies - atai Life Sciences, with its DMT oral film in Phase II trials for TRD, saw its stock drop by over 15% [3]. - MindMed, which is in Phase III trials for an LSD derivative targeting major depressive disorder, experienced a stock decline of approximately 6% [3]. - Cybin's stock, which is developing an oral psilocin treatment for depression in Phase II trials, fell by about 5% [3]. - GH Research, with its inhaled mebufotenin candidate in Phase II for TRD, also saw a stock decrease of around 5% [3]. - Other psychedelic stocks, including Clearmind Medicine, Enveric Biosciences, and Bright Minds Biosciences, faced significant declines on the same day [4].